Avastin meets Phase III RCC endpoint

By BC Staff | Dec 13, 2006 | 2:26 AM GMT

Genentech (DNA) said Avastin bevacizumab plus interferon alpha-2a met the primary

Read the full 116 word article

How to gain access

Continue reading with a
two-week free trial.